UBS analyst Kavya Deshpande initiated coverage of Elekta (EKTAY) with a Sell rating and SEK 34 price target The firm’s analysis suggests the radiotherapy market is slowing meaningfully and that Elekta is unlikely to compensate with share gains.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EKTAY: